Literature DB >> 10562702

Thalidomide as an emerging immunotherapeutic agent.

J B Marriott1, G Muller, A G Dalgleish.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10562702     DOI： 10.1016/s0167-5699(99)01531-5

Source DB:  PubMed          Journal:  Immunol Today        ISSN： 0167-5699


× No keyword cloud information.
  24 in total

1.  Generating hypotheses by discovering implicit associations in the literature: a case report of a search for new potential therapeutic uses for thalidomide.

Authors:  Marc Weeber; Rein Vos; Henny Klein; Lolkje T W De Jong-Van Den Berg; Alan R Aronson; Grietje Molema
Journal:  J Am Med Inform Assoc       Date:  2003-01-28       Impact factor: 4.497

2.  Differential surface expression of CD18 and CD44 by neutrophils in bone marrow and spleen contributed to the neutrophilia in thalidomide-treated female B6C3F1 mice.

Authors:  Wimolnut Auttachoat; Jian Feng Zheng; Rui P Chi; Andrew Meng; Tai L Guo
Journal:  Toxicol Appl Pharmacol       Date:  2006-11-22       Impact factor: 4.219

3.  Effect of TNF-α production inhibitors on the production of pro-inflammatory cytokines by peripheral blood mononuclear cells from HTLV-1-infected individuals.

Authors:  T Luna; S B Santos; M Nascimento; M A F Porto; A L Muniz; E M Carvalho; A R Jesus
Journal:  Braz J Med Biol Res       Date:  2011-10-22       Impact factor: 2.590

4.  Thalidomide inhibits granulocyte responses in healthy humans after ex vivo stimulation with bacterial antigens.

Authors:  N P Juffermans; A Verbon; M J Schultz; C E Hack; S J van Deventer; P Speelman; T van der Poll
Journal:  Antimicrob Agents Chemother       Date:  2001-05       Impact factor: 5.191

5.  Intravesical Thalidomide boosts bacillus Calmette-Guérin (BCG) in non-muscle invasive bladder cancer treatment.

Authors:  Gabriela R Passos; Juliana A Camargo; Karen L Ferrari; Mário J A Saad; Amilcar C de Mattos; Leonardo O Reis
Journal:  Med Oncol       Date:  2017-12-04       Impact factor: 3.064

6.  Potent inhibition of cytokine production from intestinal lamina propria T cells by phosphodiesterase-4 inhibitory thalidomide analogues.

Authors:  J L Prehn; C Landers; G W Muller; H W Man; D I Stirling; S R Targan
Journal:  J Clin Immunol       Date:  2001-09       Impact factor: 8.317

7.  Thalidomide and its analogues have distinct and opposing effects on TNF-alpha and TNFR2 during co-stimulation of both CD4(+) and CD8(+) T cells.

Authors:  J B Marriott; I A Clarke; K Dredge; G Muller; D Stirling; A G Dalgleish
Journal:  Clin Exp Immunol       Date:  2002-10       Impact factor: 4.330

8.  Resolving a double standard for risk management of thalidomide: an evaluation of two different risk management programmes in Japan.

Authors:  Nobuhiro Ooba; Tsugumichi Sato; Hikaru Watanabe; Kiyoshi Kubota
Journal:  Drug Saf       Date:  2010-01-01       Impact factor: 5.606

Review 9.  [Dermatological symptoms in rheumatology].

Authors:  E Aberer
Journal:  Z Rheumatol       Date:  2008-09       Impact factor: 1.372

10.  Etiology and Management of Recurrent Aphthous Stomatitis.

Authors:  Martin S. Greenberg; Andres Pinto
Journal:  Curr Infect Dis Rep       Date:  2003-06       Impact factor: 3.725
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.